{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:15:32Z","timestamp":1789683332450,"version":"4.0.1"},"reference-count":53,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Objective: This umbrella review synthesizes and critically appraises the evidence on the efficacy and safety of tegoprazan-based versus proton pump inhibitor (PPI)-based regimens for Helicobacter pylori (H. pylori) eradication. Methods: This umbrella review was pre-registered in PROSPERO (CRD420251271120). Systematic reviews and meta-analyses published between 1 January 2018 and 10 December 2025 were identified through MEDLINE\/PubMed, EMBASE, and the Cochrane Library. Reviews comparing tegoprazan-based and PPI-based eradication regimens in adult patients were included. Methodological quality was assessed using AMSTAR-2, risk of bias with ROBIS, and certainty of evidence with GRADE. Pooled relative risks (RRs) were calculated, with subgroup analyses by study design, treatment duration, and therapeutic regimen. Results: Eight systematic reviews and meta-analyses encompassing 17 primary studies and 12,714 participants were included. Tegoprazan-based regimens were associated with a statistically significant improvement in eradication efficacy compared with PPI-based therapies (RR = 1.019; 95% CI: 1.003\u20131.035; p = 0.021). In randomized controlled trials, the benefit was more pronounced (RR = 1.037; 95% CI: 1.015\u20131.061; p = 0.001), whereas no statistically significant benefit was observed in non-randomized studies (RR = 1.014; 95% CI: 0.991\u20131.037; p = 0.235). The efficacy advantage was mainly confined to quadruple therapy regimens (RR = 1.044; 95% CI: 1.002\u20131.088; p = 0.038). Tegoprazan-based regimens were associated with a lower incidence of overall adverse events compared with the PPI group (RR = 0.930; 95% CI: 0.885\u20130.976; p = 0.003). Conclusions: Tegoprazan-containing regimens were associated with a modest but statistically significant improvement in H. pylori eradication compared with PPI-containing regimens, particularly in randomized controlled trials and quadruple therapy regimens.<\/jats:p>","DOI":"10.3390\/ph19040637","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T16:30:36Z","timestamp":1776443436000},"page":"637","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Tegoprazan in Helicobacter pylori Eradication: An Umbrella Review of Meta-Analyses"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-7112","authenticated-orcid":false,"given":"Dmitrii N.","family":"Andreev","sequence":"first","affiliation":[{"name":"Department of Internal Disease Propaedeutics and Gastroenterology, Russian University of Medicine, 127473 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alsu R.","family":"Khurmatullina","sequence":"additional","affiliation":[{"name":"Department of Internal Disease Propaedeutics and Gastroenterology, Russian University of Medicine, 127473 Moscow, Russia"},{"name":"Institute of Clinical Medicine, I. M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor V.","family":"Maev","sequence":"additional","affiliation":[{"name":"Department of Internal Disease Propaedeutics and Gastroenterology, Russian University of Medicine, 127473 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2815-3992","authenticated-orcid":false,"given":"Dmitry S.","family":"Bordin","sequence":"additional","affiliation":[{"name":"Department of Internal Disease Propaedeutics and Gastroenterology, Russian University of Medicine, 127473 Moscow, Russia"},{"name":"Department of Pancreatic, Biliary and Upper Digestive Tract Disorders, A. S. Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia"},{"name":"Department of General Medical Practice and Family Medicine, Tver State Medical University, 170100 Tver, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey V.","family":"Zaborovskiy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Russian University of Medicine, 127473 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7760-2091","authenticated-orcid":false,"given":"Yury A.","family":"Kucheryavyy","sequence":"additional","affiliation":[{"name":"Ilyinskaya Hospital, 143421 Krasnogorsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipp S.","family":"Sokolov","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Russian University of Medicine, 127473 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr A.","family":"Beliy","sequence":"additional","affiliation":[{"name":"Department of Internal Disease Propaedeutics and Gastroenterology, Russian University of Medicine, 127473 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: The Maastricht VI\/Florence consensus report","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","article-title":"ACG Clinical Guideline: Treatment of Helicobacter pylori Infection","volume":"119","author":"Chey","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S2468-1253(23)00070-5","article-title":"Global prevalence of Helicobacter pylori infection between 1980 and 2022: A systematic review and meta-analysis","volume":"8","author":"Li","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1053\/j.gastro.2023.12.022","article-title":"Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022","volume":"166","author":"Chen","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.3748\/wjg.v30.i43.4636","article-title":"Prevalence of Helicobacter pylori infection in China from 2014\u20132023: A systematic review and meta-analysis","volume":"30","author":"Xie","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Andreev, D.N., Khurmatullina, A.R., Maev, I.V., Bordin, D.S., Abdulkhakov, S.R., Kucheryavyy, Y.A., Beliy, P.A., and Sokolov, F.S. (2025). The Prevalence of Helicobacter pylori Infection in the Adult Population of Russia: A Systematic Review and Meta-Analysis. Epidemiologia, 6.","DOI":"10.3390\/epidemiologia6030047"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41572-023-00431-8","article-title":"Helicobacter pylori infection","volume":"9","author":"Malfertheiner","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/gut.2009.192757","article-title":"Helicobacter pylori treatment in the era of increasing antibiotic resistance","volume":"59","author":"Graham","year":"2010","journal-title":"Gut"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00228-025-03850-6","article-title":"Tegoprazan: A novel, highly selective, and potent potassium-competitive acid blocker (P-CAB)","volume":"81","author":"Wang","year":"2025","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Andreev, D.N., Khurmatullina, A.R., Maev, I.V., Bordin, D.S., Zaborovsky, A.V., Kucheryavyy, Y.A., Sokolov, P.S., and Beliy, P.A. (2025). Tailored Therapy vs. Empirical Therapy for Helicobacter pylori Eradication: An Umbrella Review of Systematic Reviews and Meta-Analyses. J. Pers. Med., 15.","DOI":"10.3390\/jpm15100458"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Maev, I.V., Khurmatullina, A.R., Andreev, D.N., Zaborovsky, A.V., Kucheryavyy, Y.A., Sokolov, P.S., and Beliy, P.A. (2026). Rebamipide as an Adjunctive Therapy for Gastrointestinal Diseases: An Umbrella Review. Pharmaceuticals, 19.","DOI":"10.3390\/ph19010144"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.3748\/wjg.v20.i18.5283","article-title":"Treatment of Helicobacter pylori infection: Current status and future concepts","volume":"20","author":"Yang","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.3748\/wjg.v25.i34.5097","article-title":"Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness","volume":"25","author":"Ierardi","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharmthera.2016.08.001","article-title":"Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases","volume":"168","author":"Inatomi","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11894-024-00939-3","article-title":"Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments","volume":"26","author":"Scarpignato","year":"2024","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_16","first-page":"693","article-title":"Potassium-Competitive Acid Blockers: Present and Potential Utility in the Armamentarium for Acid Peptic Disorders","volume":"18","author":"Wong","year":"2022","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/jpet.117.244202","article-title":"Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility","volume":"364","author":"Takahashi","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_18","first-page":"611","article-title":"Current status and prospects of using potassium-competitive acid blockers in gastroenterology","volume":"97","author":"Maev","year":"2025","journal-title":"Ter. Arkhiv"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1111\/bcp.15268","article-title":"Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole","volume":"88","author":"Yang","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s40262-023-01228-4","article-title":"Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole","volume":"62","author":"Yang","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Liu, J., and Hahn, J. (2025). Clinical pharmacokinetics of potassium competitive acid blockers: A systematic review and meta-analysis. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1580969"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/1751-2980.70004","article-title":"Tegoprazan as First- and Second-Line Therapy for Eradication of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis","volume":"26","author":"Purja","year":"2025","journal-title":"J. Dig. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e70134","DOI":"10.1002\/jgh3.70134","article-title":"Tegoprazan-Containing Versus Proton Pump Inhibitor-Containing Therapy for First-Line Eradication of Helicobacter pylori: A Meta-Analysis of Randomized Controlled Trials","volume":"9","author":"Simadibrata","year":"2025","journal-title":"JGH Open"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/XEB.0000000000000055","article-title":"Summarizing systematic reviews","volume":"13","author":"Aromataris","year":"2015","journal-title":"Int. J. Evid. Based Healthc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1503\/cmaj.081086","article-title":"Integration of evidence from multiple meta-analyses: A primer on umbrella reviews, treatment networks and multiple treatments meta-analyses","volume":"181","author":"Ioannidis","year":"2009","journal-title":"Can. Med. Assoc. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jclinepi.2015.06.005","article-title":"ROBIS: A new tool to assess risk of bias in systematic reviews was developed","volume":"69","author":"Whiting","year":"2016","journal-title":"J. Clin. Epidemiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jrsm.1557","article-title":"Graphical Representation of Overlap for OVErviews: GROOVE tool","volume":"13","author":"Bracchiglione","year":"2022","journal-title":"Res. Synth. Methods"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562848241241223","article-title":"P-CAB versus PPI in the eradication of Helicobacter pylori: A systematic review and network meta-analysis","volume":"17","author":"Jiang","year":"2024","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3748\/wjg.v30.i9.1213","article-title":"Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis","volume":"30","author":"Kanu","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562848251314801","article-title":"The efficacy and safety of Vonoprazan and Tegoprazan in Helicobacter pylori eradication: A comprehensive systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Jin","year":"2025","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/14787210.2025.2459722","article-title":"Comparison of tegoprazan and proton pump inhibitors for first-line Helicobacter pylori eradication: A systematic review with meta-analysis","volume":"23","author":"Cho","year":"2025","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"100705","DOI":"10.1016\/j.gastha.2025.100705","article-title":"Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker\u2013 and Proton Pump Inhibitor\u2013Based Bismuth Quadruple Therapy for Helicobacter pylori Eradication: A Network Meta-Analysis","volume":"4","author":"Taufiqqurrachman","year":"2025","journal-title":"Gastro Hep Adv."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Zhang, X., Li, X., Li, J., Deng, Y., Xu, W., Chen, D., and Wei, L. (2025). Comparison of tegoprazan-based and proton pump inhibitor-based regimens for Helicobacter pylori eradication: A meta-analysis and systematic review. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1580203"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ho, C.-Y., Liu, T.-W., Lin, Y.-S., Chen, Y.-P., Chen, M.-J., Wang, H.-Y., and Liou, T.-C. (2022). Factors Affecting the Intraluminal Therapy for Helicobacter pylori Infection. Microorganisms, 10.","DOI":"10.3390\/microorganisms10020415"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/39.1.5","article-title":"The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: Relevance to the treatment of Helicobacter pylori infection","volume":"39","author":"Erah","year":"1997","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ueg2.12476","article-title":"Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management","volume":"12","author":"Saracino","year":"2024","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1365-2036.2008.03807.x","article-title":"Meta-analysis: High-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication","volume":"28","author":"Villoria","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1046\/j.1365-2036.2002.01270.x","article-title":"Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: A meta-analysis","volume":"16","author":"Vallve","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Jeong, H.-C., Kim, M.-G., Wei, Z., Lee, K.-R., Lee, J., Song, I.-S., and Shin, K.-H. (2022). Integration of a Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Tegoprazan and Its Metabolite: Application for Predicting Food Effect and Intragastric pH Alterations. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061298"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Hossa, K., and Ma\u0142ecka-Wojciesko, E. (2025). Advances in Gastroesophageal Reflux Disease Management: Exploring the Role of Potassium-Competitive Acid Blockers and Novel Therapies. Pharmaceuticals, 18.","DOI":"10.3390\/ph18050699"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e15121","DOI":"10.7717\/peerj.15121","article-title":"The prevalence of clarithromycin-resistant Helicobacter pylori isolates: A systematic review and meta-analysis","volume":"11","author":"Sholeh","year":"2023","journal-title":"PeerJ"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Andreev, D.N., Khurmatullina, A.R., Maev, I.V., Bordin, D.S., Zaborovskiy, A.V., Abdulkhakov, S.R., Kucheryavyy, Y.A., Sokolov, F.S., and Beliy, P.A. (2025). Helicobacter pylori Antibiotic Resistance in Russia: A Systematic Review and Meta-Analysis. Antibiotics, 14.","DOI":"10.3390\/antibiotics14050524"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.14309\/ajg.0000000000001828","article-title":"Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis","volume":"117","author":"Ho","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.cmi.2019.06.007","article-title":"Antimicrobial resistance of Helicobacter pylori in Germany, 2015 to 2018","volume":"26","author":"Bluemel","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1128\/CMR.00033-06","article-title":"Helicobacter pylori Detection and Antimicrobial Susceptibility Testing","volume":"20","author":"Megraud","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"13432","DOI":"10.3748\/wjg.v21.i48.13432","article-title":"High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment","volume":"21","author":"Zhang","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"114","DOI":"10.12793\/tcp.2023.31.e11","article-title":"Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects","volume":"31","author":"Oh","year":"2023","journal-title":"Transl. Clin. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00228-025-03912-9","article-title":"Optimizing acid-related disease management: Insights into potassium-competitive acid blockers and proton pump inhibitors","volume":"81","author":"Shang","year":"2025","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Zhao, X., Zhang, Z., Lu, F., Xiong, M., Jiang, L., Tang, K., Fu, M., Wu, Y., and He, B. (2022). Effects of CYP2C19 genetic polymorphisms on the cure rates of H. pylori in patients treated with the proton pump inhibitors: An updated meta-analysis. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.938419"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","article-title":"Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial","volume":"163","author":"Chey","year":"2022","journal-title":"Gastroenterology"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/4\/637\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T04:24:08Z","timestamp":1777004648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/4\/637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":53,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["ph19040637"],"URL":"https:\/\/doi.org\/10.3390\/ph19040637","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]}}}